MELA Sciences, Inc., A Leader In The Fight Against Melanoma, Hosts Symposium At 8th World Congress Of Melanoma

 MELA Sciences, Inc., A Leader In The Fight Against Melanoma, Hosts Symposium
                      At 8th World Congress Of Melanoma

PR Newswire

IRVINGTON, N.Y., July 22, 2013

IRVINGTON, N.Y., July 22, 2013 /PRNewswire/ --MELA Sciences, Inc. (NASDAQ:
MELA), the medical device company that has developed and is commercializing
MelaFind®, the first and only FDA approved optical diagnostic device for
melanoma detection used by dermatologists in their fight against melanoma,
presented at the 8th World Congress of Melanoma held in Hamburg, Germany, on
July 19, 2013, to a well-attended room. 

(Logo: http://photos.prnewswire.com/prnh/20130103/NY36051LOGO)

The symposium, led by Axel Hauschild, MD, PhD, Professor and Head of the
Interdisciplinary Skin Cancer Center at the Department of Dermatology,
University Hospital Schleswig-Holstein in Kiel, Germany, and by Andreas Blum
MD, PhD, Associate Professor of Dermatology at the Medical University of
Tuebingen, Germany, and Public, Private and Teaching Practice Dermatology,
Konstanz, Germany, focused on mole management and incorporating MelaFind®
technology into skin examinations. A panel on "Managing Melanocytic Nevi: How
it's Done Today & MelaFind®'s Place in This World," was led by Dr. Blum,
followed by an open discussion led by Dr. Hauschild on "Detecting Early
Melanomas: MelaFind® Clinical Studies, International Perspectives on Mole
Management 2013 & Beyond."

According to data presented by Dr. Hauschild, the detection, diagnosis and
management of melanoma by dermatologists improves when using the information
generated by MelaFind®. "The additional, objective information and images of a
lesion 2.5 mm below the skin surface that MelaFind® offers, when combined with
the clinical expertise of dermatologists, leads to a clinically significant
increase of thin melanomas detected at the earliest, most curable stage of the
disease," said Dr. Hauschild. "Early detection or rule out is the first step
in proper melanoma management and the objective analytical information from
MelaFind® clearly helps."

"As leading dermatologists will tell you, survival rate for melanoma
significantly improves when detected at its earliest stages and the additional
clinical information provided by MelaFind®, as the only optical diagnostic
tool that sees 2.5 mm below the skin surface, helps dermatologists effectively
find melanomas when they are most curable," said Robert Coradini, Interim CEO
for MELA Sciences. "MelaFind® is being successfully implemented in
dermatologists' offices across Germany and the United States, and we are
pleased to show our research at the World Congress to raise awareness of
MelaFind® as the new standard of care for melanoma detection and management."

MelaFind® has been recognized by the Cleveland Clinic as a Top 10 Medical
Innovation for 2013. Consumers can learn more about the device or locate a
dermatologist with MelaFind® in their area by visiting www.melafind.com.

About MELA Sciences, Inc.
MELA Sciences is a medical device company focused on the commercialization of
its flagship product, MelaFind® ^ and its further design and development.
MelaFind® is a non-invasive tool to provide additional information to
dermatologists during melanoma skin examinations. The device uses light from
visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm
beneath the skin. The device provides information on a lesion's level of
morphologic disorganization to provide additional objective information that
may be used by dermatologists in the biopsy decision-making process. MelaFind®
has been approved by the US Food and Drug Administration for use in the US. In
addition, MelaFind® has received CE Mark approval and is approved for use in
the European Union.

For more information on MELA Sciences, visit www.melasciences.com.

Safe Harbor:
This press release includes "forward-looking statements" within the meaning of
the Securities Litigation Reform Act of 1995. These statements include but are
not limited to our plans, objectives, expectations and intentions and other
statements that contain words such as "expects," "contemplates,"
"anticipates," "plans," "intends," "believes," "assumes," "predicts" and
variations of such words or similar expressions that predict or indicate
future events or trends, or that do not relate to historical matters. These
statements are based on our current beliefs or expectations and are inherently
subject to significant known and unknown uncertainties and changes in
circumstances, many of which are beyond our control. There can be no assurance
that our beliefs or expectations will be achieved. Actual results may differ
materially from our beliefs or expectations due to financial, economic,
business, competitive, market, regulatory and political factors or conditions
affecting the company and the medical device industry in general, as well as
more specific risks and uncertainties facing the company such as those set
forth in its reports on Forms 10-Q and 10-K filed with the U.S. Securities and
Exchange Commission (the "SEC"). Factors that might cause such a difference
include whether MelaFind® achieves market acceptance. Given the uncertainties
affecting companies in the medical device industry such as the Company, any or
all of these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements. The
Company urges you to carefully review and consider the disclosures found in
its filings with the SEC which are available at www.sec.gov and
www.melasciences.com.

SOURCE MELA Sciences, Inc.

Website: http://www.melasciences.com
Contact: Investors, Lynn Pieper, Westwicke Partners, 415-202-5678, Media,
Erica Sperling, Rpr Marketing Communications, 212-317-1462,
Erica.Sperling@rprmc.com
 
Press spacebar to pause and continue. Press esc to stop.